Atty Dkt 4364-0002.22

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 24 Feb. 1995

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Raju Kucherlapati et al.

MAR 1 5 1995 Group Art Unit: 1804

Serial No.: 08/031,801

GROUP TEXAminer: S. Ziska

Title: GENERATION OF XENOGENEIC

ANTIBODIES

Filing Date: 15 March 1993

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In addition to the Information Disclosure Statement Under 37 CFR 1.97 mailed to the PTO on 24 September 1993, the citations on the attached sheet, copies attached, were cited in an International Search Report (copy attached) in the corresponding European Application and may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure as defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in the application.

- 1. U.S. Patent No. 4,959,313 to Taketo issued on 25 September 1990.
- 2. U.S. Patent No. 4,950,599 to Bertling issued on 21 August 1990.

120 KM 03/14/95 08031801


210.00 CK

- 3. Yamaura et al., "Cell-Type-Specific and Regulated Expression of a Human γ 1 Heavy-Chain Immunoglobulin Gene in Transgenic Mice", *Proc. Natl. Acad. Sci.*, *USA* 83:2152-2156 (1986).
- 4. Ayares et al., "Sequence Homology Requirements for Intermolecular Recombination in Mammalian Cells", *Proc. Natl. Acad. Sci. USA* 83:5199-5203 (1986).
- 5. Brinster et al., "Introns Increase Transcriptional Efficiency in Transgenic Mice", *Proc. Natl. Acad. Sci.*, USA 85:836-840 (1988).
- 6. Kucherlapalati, R., "Homologous Recombination in Mammalian Somatic Cells", *Prog. Nucleic Acid Res. Mol. Biol. 36:*301-310 (1989).
- 7. Shimizu et al., "Immunoglobulin Double-Isotype Expression by Trans-mRNA in a Human Immunoglobulin Transgenic Mouse", *Proc. Natl. Acad. Sci., USA* 86:8020-8023 (1989).

This Information Disclosure Statement is submitted following receipt of the first Office Action, but before issuance of a Final Office Action or Notice of Allowance. A check in the amount of \$210.00 is attached in payment of the fee set forth in 37 CFR 1.17(p).

The Commissioner is hereby authorized to charge payment of any deficiency in the above fee, charge any additional fees which may be required by this paper or credit any overpayment to Deposit Account Number 03-1952. A duplicate copy of this authorization is attached for such purposes.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.



This Supplemental Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 U.S.C. § 102.

Respectfully submitted,

Kate H. Murashige

Registration No. 29,959

MORRISON & FOERSTER 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1812

Tel: (202) 887-1500 Fax: (202) 887-0763

572